Your browser doesn't support javascript.
loading
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies.
Farokhnia, Mehdi; Rentsch, Christopher T; Chuong, Vicky; McGinn, M Adrienne; Elvig, Sophie K; Douglass, Eliza A; Gonzalez, Luis A; Sanfilippo, Jenna E; Marchette, Renata C N; Tunstall, Brendan J; Fiellin, David A; Koob, George F; Justice, Amy C; Leggio, Lorenzo; Vendruscolo, Leandro F.
Afiliación
  • Farokhnia M; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Instit
  • Rentsch CT; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
  • Chuong V; VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven, CT, USA.
  • McGinn MA; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Elvig SK; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
  • Douglass EA; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Instit
  • Gonzalez LA; Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Sanfilippo JE; Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Marchette RCN; Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Tunstall BJ; Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Fiellin DA; Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Koob GF; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Instit
  • Justice AC; Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Leggio L; Neurobiology of Addiction Section, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Vendruscolo LF; Department of Pharmacology, Addiction Science, and Toxicology, University of Tennessee Health Science Center, Memphis, TN, USA.
Mol Psychiatry ; 27(11): 4642-4652, 2022 Nov.
Article en En | MEDLINE | ID: mdl-36123420

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Alcoholismo Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Mol Psychiatry Asunto de la revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Alcoholismo Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Mol Psychiatry Asunto de la revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Año: 2022 Tipo del documento: Article